Parkinson's disease
Conditions
Interventions
None listed
Sponsors
Radboud Universiteit Nijmegen
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: General: 1) *40 years old. 2) Able to read and understand Dutch. 3) Subject is willing, competent, and able to comply with all aspects of the protocol, including follow-up schedule. Parkinson's Disease-specific: 1) Participation in motor and reward tasks Personalized Parkinson Project (NL59694.091.16) 2) Subject has Parkinson*s disease of *5 years* duration, defined as time since diagnosis made by a neurologist.
Exclusion criteria
Exclusion criteria: 1) Subject has co-morbidities that would hamper interpretation of parkinsonian disability or task performance, such as coincident musculoskeletal abnormalities, in the opinion of the investigator. 2) Contraindicated for MRI, e.g., claustrophobia, presence of an active implant, pacemaker, insulin pump, neurostimulator, ossicle prosthesis, pregnancy, and/or other medical device or other non-removable metal part incompatible with MRI.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| For this study, we will assess 50 patients with PD once (OFF their dopaminergic medication) and 50 healthy volunteers twice (baseline and two-year follow up). We will use a subset of the protocols used in the PPP, in which 650 PD patients are assessed ON their dopaminergic medication. This protocol includes two functional MRI tasks (motor task in first half (n=325) of patients, reward task in second half (n=325) of patients) that quantify both (dysfunctional) processing in the basal ganglia and (compensatory) processing in the cortex (i.e. parietal cortex for the motor task, orbito-frontal cortex for the reward task). We will quantify clinical disease progression with clinical measures such as the MDS-UPDRS. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary study parameters include participant characteristics (e.g. Age, Gender, Comorbidity, Medication use), clinical measures (e.g. severity of motor, cognitive and neuropsychiatric symptoms), and additional MRI-measures (Resting state functional connectivity, Diffusion tensor imaging, Quantitative susceptibility imaging and fluid-attenuated inversion recovery) to be used for thorough interpretation of primary outcomes. | — |
Countries
Netherlands
Outcome results
None listed